title: MiR-346 and TRAb as Predicative Factors for Relapse in Graves' Disease Within One Year.
abstract: Despite the efficacy and safety, antithyroid drug (ATD) therapy for Graves' disease (GD) is associated with a high risk of relapse, especially within the first year. The inability to predict whether and when relapse may occur is a major problem for ATD therapy. This study was aimed to investigate potential predicative factors for GD patients after ATD withdrawal. Consecutive patients newly diagnosed with GD and treated with ATD [methimazole (MMI)] were enrolled in this study. Univariate and multivariate Cox proportional hazard analyses were used for the analysis of predicative parameters for GD relapse after MMI withdrawal. Kaplan-Meier survival analysis and log-rank test were utilized for presenting the risk of relapse. Of the 103 patients included, 67 (65.0%) remained in remission and 36 (35.0%) had a relapse within 1 year after the MMI withdrawal. The multivariate analysis suggested significant predictive factors for GD relapse: patients with higher miR-346 expressions (≥median value) at diagnosis and at cessation, and lower TRAb levels at cessation. MiR-346 at diagnosis and cessation, and TRAb at cessation could serve as predictive factors for GD relapse within 1 year after drug withdrawal.
authors.affiliation: Department of Endocrine, Ningbo No. 2 Hospital, Ningbo City, Zhejiang Province, China.
authors.forename: Jianhui
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Geriatrics, Ningbo No. 2 hospital.
authors.forename: Yawei
authors.initials: Y
authors.lastname: Cai
authors.affiliation: Department of Endocrine, Ningbo No. 2 Hospital, Ningbo City, Zhejiang Province, China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Endocrine, Ningbo No. 2 Hospital, Ningbo City, Zhejiang Province, China.
authors.forename: Danzhen
authors.initials: D
authors.lastname: Yao
authors.affiliation: Department of Endocrine, Ningbo No. 2 Hospital, Ningbo City, Zhejiang Province, China.
authors.forename: Jinying
authors.initials: J
authors.lastname: Xia
mesh_terms: D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating / Q000097:blood*; D008297:Male; D008713:Methimazole / Q000008:administration & dosage*; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate
chemical_list: D018828:Immunoglobulins, Thyroid-Stimulating; C560923:MIRN346 microRNA, human; D035683:MicroRNAs; D008713:Methimazole